Key facts
- This page summarizes Stephen Davis's Form 4 filing for ACADIA PHARMACEUTICALS INC (ACAD).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 10 Jan 2022, 17:22.
Stephen Davis - 06 Jan 2022 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)
- Reporting relationship
- CEO, Director
- Issuer ticker
- ACAD
- Reported as of
- 06 Jan 2022
- Net transaction value
- -$85,700
- SEC form
- 4
- Accepted by SEC
- 10 Jan 2022, 17:22:58 UTC
- Prior SEC filing
- 06 Jan 2022
- Next SEC filing
- 25 Feb 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Austin D. Kim, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Stephen Davis filed Form 4 for ACADIA PHARMACEUTICALS INC (ACAD) on 10 Jan 2022.
Change
- Previous filing in this sequence was filed on 06 Jan 2022.
- Current net transaction value: -$85,700.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ACAD
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +9,527
- Change %
- +18%
- Price
- Shares after
- 62,434
- Date
- 06 Jan 2022
- Ownership
- Direct
- Footnotes
- F1, F2
ACAD
transaction
Common Stock
Sale
- Transaction value
- $85,700
- Shares
- -3,718
- Change %
- -6%
- Price
- $23.05
- Shares after
- 58,716
- Date
- 06 Jan 2022
- Ownership
- Direct
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ACAD
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -9,527
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 19,056
- Date
- 06 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,527
- Exercise price
- Footnotes
- F1, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Footnote F2
Includes 1 share of the Issuer's common stock acquired by the reporting person on November 15, 2021 pursuant to an employee stock purchase program.
Footnote F3
The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
Footnote F4
The restricted stock units vest in four equal annual installments beginning January 6, 2021.